Company Overview
Claritev Corporation operates within the healthcare sector, specifically focusing on the health information services industry, where it provides data analytics and technology-enabled solutions for cost management, payment processing, and revenue integrity. The company's core offerings include claims intelligence solutions and reference-based pricing tools designed to serve the United States healthcare market. In terms of scale, Claritev holds a market capitalization of $263.50M and generates annual revenue of $965.41M, employing a workforce of 3000 individuals. These financial metrics indicate a mid-cap enterprise with substantial revenue generation capabilities relative to its market value, suggesting a position where valuation is significantly detached from current earnings performance. The disparity between its $965.41M in revenue and a market cap of $263.50M highlights a capital market assessment that prioritizes future earnings potential or strategic positioning over current profitability metrics.
Financial Health
Claritev reports a Trailing Twelve Months (TTM) revenue of $965.41M, yet it recorded a net income of $-284,281,984, while maintaining an EBITDA of $535.44M. The significant gap between the positive EBITDA of $535.44M and the negative net income reveals a cost structure where interest expenses and taxes are substantial enough to erase operating profitability, resulting in a loss for shareholders. Despite the negative net income, the company generated free cash flow of $165.65M, which indicates a degree of financial flexibility allowing for operational reinvestment or debt servicing without immediate reliance on external equity financing. The company demonstrates a gross margin of 73.8%, reflecting high efficiency in converting revenue into gross profit before operating expenses, while the operating margin stands at 9.8%, showing that operating expenses consume a significant portion of gross profits. However, the profit margin is negative at -29.4%, confirming that the bottom line is currently unsustainable due to the heavy burden of non-operating costs. Regarding liquidity and leverage, Claritev holds $16.81M in cash against total debt of $4.62B, resulting in a debt-to-equity ratio that is not explicitly calculable in standard terms due to negative equity, though the debt load is massive relative to cash reserves. The current ratio is 0.86, which indicates that the company's current assets are insufficient to cover its current liabilities, signaling potential short-term liquidity pressure. Return on Equity is not available due to negative shareholder equity, but Return on Assets is 1.1%, suggesting that the asset base generates a minimal positive return before financing costs are applied.
Valuation Assessment
The valuation metrics for Claritev show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is 2.27, implying that the market prices the stock based on expected future earnings rather than historical performance. The price-to-book ratio is -1.48, indicating that the stock trades below the book value of assets, a condition typical for companies with significant debt or accumulated losses that erode equity value. Alternative valuation measures such as the price-to-sales ratio of 0.27 and an EV/EBITDA of 9.09 suggest that the market values the company at a fraction of its sales, potentially reflecting skepticism about its ability to restore profitability quickly. Regarding price volatility, the 52-week high is $74.07 and the 52-week low is $12.04, meaning the current market price sits significantly below the recent peak and trades at a level that reflects a substantial discount from its recent maximum trading price. The stock exhibits a beta of 0.68, which indicates that the company's price movements are less volatile than the broader market, suggesting a defensive characteristic relative to the general equity index.
Growth & Income
Claritev has achieved a revenue growth rate of 6.2% year-over-year, whereas earnings growth is N/A due to the company's current loss position, implying that top-line expansion is occurring without a corresponding increase in net income. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available cash flow back into operations rather than distributing income to shareholders. The absence of a dividend program combined with the reinvestment of free cash flow suggests a growth-oriented strategy where capital is allocated to expand the claims intelligence and revenue integrity business segments. Overall, the company's profile is characterized by steady revenue expansion and a reinvestment strategy that prioritizes operational scaling over shareholder distributions, despite the challenges presented by high debt levels and negative net income.